Protox Therapeutics Inc. announced today that it has filed a provisional patent application with the United States Patent and Trademark Office entitled “Modified Pore-Forming Toxins and Use Thereof”. This is a foundational patent application, intended to encompass and protect several aspects of the Company’s entire PORxin™ technology. Under this application the Company’s ability to develop individual protoxin candidates to act as either “broad spectrum” anti-cancer agents or to treat specific cancer types would be protected.
